Trade Alzamend Neuro, Inc. - ALZN CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.0110 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023346% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001124% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 0.01 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 0.6848 |
| Open | 0.6758 |
| 1-Year Change | -4.1% |
| Day's Range | 0.6659 - 0.6848 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 24, 2025 | 0.6848 | 0.0200 | 3.01% | 0.6648 | 0.6948 | 0.6456 |
| Apr 23, 2025 | 0.6799 | -0.0049 | -0.72% | 0.6848 | 0.6951 | 0.6660 |
| Apr 22, 2025 | 0.6812 | 0.0049 | 0.72% | 0.6763 | 0.6949 | 0.6648 |
| Apr 21, 2025 | 0.6708 | -0.0040 | -0.59% | 0.6748 | 0.6849 | 0.6648 |
| Apr 17, 2025 | 0.6633 | -0.0415 | -5.89% | 0.7048 | 0.7048 | 0.6548 |
| Apr 16, 2025 | 0.6981 | -0.0567 | -7.51% | 0.7548 | 0.7548 | 0.6981 |
| Apr 15, 2025 | 0.7542 | -0.0446 | -5.58% | 0.7988 | 0.7988 | 0.7448 |
| Apr 14, 2025 | 0.7648 | -0.0301 | -3.79% | 0.7949 | 0.7949 | 0.7348 |
| Apr 11, 2025 | 0.7336 | -0.0612 | -7.70% | 0.7948 | 0.7948 | 0.7159 |
| Apr 10, 2025 | 0.7459 | -0.0439 | -5.56% | 0.7898 | 0.7948 | 0.7281 |
| Apr 9, 2025 | 0.7848 | -0.0400 | -4.85% | 0.8248 | 0.8248 | 0.7748 |
| Apr 8, 2025 | 0.8751 | -0.0520 | -5.61% | 0.9271 | 0.9514 | 0.8448 |
| Apr 7, 2025 | 0.9148 | -0.0200 | -2.14% | 0.9348 | 0.9348 | 0.8448 |
| Apr 4, 2025 | 0.9646 | -0.0282 | -2.84% | 0.9928 | 0.9948 | 0.9283 |
| Apr 3, 2025 | 1.0048 | 0.0100 | 1.01% | 0.9948 | 1.0348 | 0.9278 |
| Apr 2, 2025 | 1.0348 | 0.0700 | 7.26% | 0.9648 | 1.0348 | 0.9258 |
| Apr 1, 2025 | 0.9851 | 0.0377 | 3.98% | 0.9474 | 0.9945 | 0.9474 |
| Mar 31, 2025 | 0.9448 | -0.0500 | -5.03% | 0.9948 | 1.0048 | 0.9258 |
| Mar 28, 2025 | 1.0448 | -0.0300 | -2.79% | 1.0748 | 1.0748 | 0.9809 |
| Mar 27, 2025 | 1.0848 | 0.1000 | 10.15% | 0.9848 | 1.0848 | 0.9564 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Alzamend Neuro, Inc. Company profile
About Alzamend Neuro Inc
Alzamend Neuro, Inc. is a preclinical stage biopharmaceutical company focused on developing products for the treatment of neurodegenerative diseases and psychiatric disorders. The Company's pipeline consists of two therapeutic drug candidates: AL001 and AL002. The AL001 is a cocrystal technology delivering a therapeutic combination of lithium, proline and salicylate, known as AL001 or LiProSal, through two royalty-bearing worldwide licenses from the University of South Florida Research Foundation, Inc. (licensor). AL002 is a patented method using a mutant peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient’s immunological system to combat Alzheimer’s, known as AL002 or CA022W, through a royalty-bearing worldwide license from the licensor.
Financial summary
BRIEF: For the nine months ended 31 January 2022, Alzamend Neuro Inc revenues was not reported. Net loss increased from $3.8M to $8.5M. Higher net loss reflects Research and development - Bal increase from $953K to $3.2M (expense), Stock-based Compensation in SGA increase of 67% to $2.8M (expense), General and administrative - Bal increase from $547K to $1.1M (expense).
| Industry: | Biotechnology & Medical Research (NEC) |
3480 Peachtree Road NE,
Second Floor, Suite 103
ATLANTA
GEORGIA 30326
US
News
ECB interest-rate forecasts – Projections for the next five years
The European Central Bank (ECB) plays a pivotal role in the economic stability of the eurozone, meaning ECB interest-rate forecasts are key to understanding how financial and economic scenarios might evolve.
14:37, 10 April 2025
BlackRock shareholders: Who owns the most BLK stock?
BlackRock is the leading asset manager in the world – but who are its biggest shareholders? Read on to find out.
13:46, 9 April 2025
Bitcoin price predictions 2025–2050: third-party price target
We examine bitcoin price predictions for 2025 and beyond, with insights from third-party analysts and market experts.
10:28, 9 April 2025
Tesla (TSLA) stock forecast 2025 and beyond: third-party Tesla price target
Where will Tesla’s stock be in five years? Can the EV company keep its crown?
08:19, 9 April 2025
JasmyCoin price predictions 2025-2030: Third-party price target
How might JASMY behave in the future?
16:13, 8 April 2025
Australian interest-rate projections: where will rates be in 5 years?
As one of the most closely watched economic indicators, Australian interest-rate projections offer valuable insight into the future of the country’s economy.
21:37, 7 April 2025
Copper price forecast: third-party price target
What’s next for the copper market? Read on for the latest analysis of the commodity's price and potential outlook.
17:31, 14 March 2025People also watch
Still looking for a broker you can trust?
Join the 720,000+ traders worldwide that chose to trade with Capital.com